Testing a new automated insulin delivery system for type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a new hybrid closed-loop system (an automated insulin pump) in people with type 1 diabetes whose blood sugar is not well controlled. It aims to see if the system is safe and helps improve glucose levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 1 diabetes and are at least 7 years old (adults up to 75).
- Your total daily insulin dose is at least 10 units and you weigh more than 22 kg (about 49 lbs).
- You or your parent/guardian can count carbohydrates and use an insulin pump or multiple daily injections.
- Your blood sugar control is not optimal (HbA1c between 7% and 12%, or time-in-range below 70%, or time-below-range above 4%).
- You use one of these rapid insulins: Humalog, Lyumjev, Novorapid, or FIASP.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new automated insulin delivery system to help people with type 1 diabetes better manage their blood sugar. It aims to see if the system improves glucose control safely.
This study tests a system that measures blood sugar and automatically adjusts insulin delivery. It is for adults with type 1 diabetes who use insulin injections or a pump.
This study compares a new automated insulin delivery algorithm (AIDANET) in two modes: fully closed-loop (no user input needed) versus hybrid closed-loop (user still gives some insulin for meals). It tests how well the algorithm works in real-life settings for adults with type 1 diabetes.
This study tests a smart insulin pump system that adjusts automatically during exercise. It aims to make managing blood sugar easier and safer.
This study tests a semi-automated insulin pump system in very young children (ages 2–6) with type 1 diabetes. It aims to see if the device improves quality of life and blood sugar control.
This study tests a new automated insulin pump system (NMX8) for adults with type 1 diabetes whose blood sugar is not well controlled (HbA1c above 7.5%). You must already be using a similar pump system. The goal is to see if this new device can help you get better control.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.